These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35307103)

  • 1. The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC.
    Wang F; Zhou Q
    J Thorac Oncol; 2022 Apr; 17(4):481-486. PubMed ID: 35307103
    [No Abstract]   [Full Text] [Related]  

  • 2. And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.
    Lau SCM; Ou SI
    J Thorac Oncol; 2022 Oct; 17(10):1144-1154. PubMed ID: 36192074
    [No Abstract]   [Full Text] [Related]  

  • 3. Lazertinib: First Approval.
    Dhillon S
    Drugs; 2021 Jun; 81(9):1107-1113. PubMed ID: 34028784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
    Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
    Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-generation EGFR-TKIs—a new hope for NSCLC.
    Akkermans R
    Lancet Respir Med; 2014 Jul; 2(7):520. PubMed ID: 25140365
    [No Abstract]   [Full Text] [Related]  

  • 6. EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.
    Park S; Ku BM; Jung HA; Sun JM; Ahn JS; Lee SH; Park K; Ahn MJ
    Cancer Res Treat; 2020 Oct; 52(4):1288-1290. PubMed ID: 32599977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
    Ni L; Nie L
    Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
    Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
    EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.
    Vansteenkiste J; Wauters E
    Ann Oncol; 2018 Jan; 29(suppl_1):i1-i2. PubMed ID: 29462258
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of advanced NSCLC with unknown EGFR gene status
--TKI or chemotherapy?].
    Liu X; Xu J
    Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):709-14. PubMed ID: 25342036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
    Tartarone A; Lerose R; Lazzari C; Gregorc V; Aieta M
    Med Oncol; 2014 Aug; 31(8):78. PubMed ID: 24958518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.
    Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciadiello F; Gridelli C
    Curr Med Chem; 2012; 19(20):3337-52. PubMed ID: 22664249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].
    Zhou M; Chen DM; Xia L; Song YY; Shi YK; Yang ZM
    Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):949-952. PubMed ID: 31874554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.
    Inoue A
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(7):266-272. PubMed ID: 32788550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irreversible EGFR inhibitors in the treatment of advanced NSCLC.
    Maione P; Rossi A; Bareschino M; Sacco PC; Schettino C; Casaluce F; Sgambato A; Gridelli C
    Curr Pharm Des; 2014; 20(24):3894-900. PubMed ID: 24138713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
    Sutandyo N; Hanafi A; Jayusman M
    Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Furmonertinib: First Approval.
    Deeks ED
    Drugs; 2021 Oct; 81(15):1775-1780. PubMed ID: 34528187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.